Alloanti-Hy in antenatal patients: A multi-case review.

IF 1.5 4区医学 Q3 HEMATOLOGY

Transfusion Medicine Pub Date : 2025-01-25 DOI:10.1111/tme.13124

S Lewis, N Kirkpatrick, A Nawrocki, L Reyland, B Jones, R Laundy, A McNeil, V Karamatic Crew, T Stutt, D Clinton, A Anbazhagan, C Harris, I Skidmore, T Bullock, M Hazell

{"title":"Alloanti-Hy in antenatal patients: A multi-case review.","authors":"S Lewis, N Kirkpatrick, A Nawrocki, L Reyland, B Jones, R Laundy, A McNeil, V Karamatic Crew, T Stutt, D Clinton, A Anbazhagan, C Harris, I Skidmore, T Bullock, M Hazell","doi":"10.1111/tme.13124","DOIUrl":null,"url":null,"abstract":"Introduction: Introduction The Hy antigen is one of ten red cell antigens belonging to the Dombrock blood group system, with an antigen frequency of almost 100% in the majority of populations. Alloantibodies to high prevalence antigens cause difficulties with antibody identification and exclusion in serological investigations.Case presentation: This review describes the management of four antenatal cases where the presence of alloanti-Hy had been identified. Hy-red blood cell units may be required for the transfusion of patients with alloanti-Hy, but currently, there are no published reports of alloanti-Hy causing haemolytic disease of the fetus and newborn (HDFN). A previous case report involving the care and management of antenatal patients with alloanti-Hy antibodies indicates a lack of evidence that alloanti-Hy causes clinical HDFN.Results: All cases discussed in this review demonstrate a reduction in the strength of alloanti-Hy levels as pregnancy progressed. Signs or symptoms of HDFN were not observed with any of the pregnancies.Conclusion: Factors such as antibody levels, antigenic expression, and varying clinical responses enhance our understanding of why alloanti-Hy has not been known to cause clinical HDFN. The cases presented here aim to improve understanding of alloanti-Hy in pregnancy and how to manage such cases.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tme.13124","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Introduction The Hy antigen is one of ten red cell antigens belonging to the Dombrock blood group system, with an antigen frequency of almost 100% in the majority of populations. Alloantibodies to high prevalence antigens cause difficulties with antibody identification and exclusion in serological investigations.

Case presentation: This review describes the management of four antenatal cases where the presence of alloanti-Hy had been identified. Hy-red blood cell units may be required for the transfusion of patients with alloanti-Hy, but currently, there are no published reports of alloanti-Hy causing haemolytic disease of the fetus and newborn (HDFN). A previous case report involving the care and management of antenatal patients with alloanti-Hy antibodies indicates a lack of evidence that alloanti-Hy causes clinical HDFN.

Results: All cases discussed in this review demonstrate a reduction in the strength of alloanti-Hy levels as pregnancy progressed. Signs or symptoms of HDFN were not observed with any of the pregnancies.

Conclusion: Factors such as antibody levels, antigenic expression, and varying clinical responses enhance our understanding of why alloanti-Hy has not been known to cause clinical HDFN. The cases presented here aim to improve understanding of alloanti-Hy in pregnancy and how to manage such cases.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Medicine 医学-血液学

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Transfusion Medicine publishes articles on transfusion medicine in its widest context, including blood transfusion practice (blood procurement, pharmaceutical, clinical, scientific, computing and documentary aspects), immunohaematology, immunogenetics, histocompatibility, medico-legal applications, and related molecular biology and biotechnology. In addition to original articles, which may include brief communications and case reports, the journal contains a regular educational section (based on invited reviews and state-of-the-art reports), technical section (including quality assurance and current practice guidelines), leading articles, letters to the editor, occasional historical articles and signed book reviews. Some lectures from Society meetings that are likely to be of general interest to readers of the Journal may be published at the discretion of the Editor and subject to the availability of space in the Journal.